Vervloet Marcia, van Dijk Liset, Spreeuwenberg Peter, Price David, Chisholm Alison, Van Ganse Eric, Pinnock Hilary, Rand Cynthia S, Eakin Michelle N, Schermer Tjard, Souverein Patrick C, Dima Alexandra L
Nivel, Netherlands Institute for Health Services Research, Utrecht, the Netherlands.
Nivel, Netherlands Institute for Health Services Research, Utrecht, the Netherlands; Department of PharmacoTherapy, -Epidemiology & -Economics (PTEE), Groningen Research Institute of Pharmacy, Faculty of Mathematics and Natural Sciences, University of Groningen, Groningen, the Netherlands.
J Allergy Clin Immunol Pract. 2020 Feb;8(2):626-634. doi: 10.1016/j.jaip.2019.09.003. Epub 2019 Sep 18.
Low inhaled corticosteroid (ICS) adherence is associated with increased asthma burden. This relationship is likely bidirectional, and may vary across adherence stages (initiation, implementation, and persistence). Studies rarely examine reciprocal influences.
To investigate the relationship between ICS implementation and asthma-related outcomes over 2 years, considering bidirectionality and temporal sequence.
Primary care records (1987-2012) from the Optimum Patient Care Research Database, United Kingdom, were used. Eligible patients were 6 years or older and had 3 or more years of continuous registration starting 1 year before ICS initiation (index date), physician-diagnosed asthma, 2 or more ICS and/or short-acting β-agonist prescriptions each follow-up year, and no long-acting β-agonists, leukotriene receptor antagonists, or maintenance oral corticosteroids in the preceding year. ICS implementation (percentage of days covered) and risk domain asthma control (RDAC; no asthma-related hospitalizations, emergency visits, or outpatient visits and no oral corticosteroid or antibiotic prescriptions with evidence of respiratory review) were estimated for each prescription interval (period between 2 successive prescriptions). Multilevel analyses modeled bidirectional relationships between ICS implementation and RDAC (and its components), controlling for sociodemographic and clinical characteristics.
In prescription data from 10,472 patients, ICS implementation in the preceding interval did not predict RDAC, but was weakly positively associated with simultaneous RDAC. Being male, non-current smoker, without chronic obstructive pulmonary disease diagnosis, and with fewer than 4 comorbidities significantly increased odds of RDAC. Asthma-related antibiotics and outpatient visits in the same interval and short-acting β-agonist overuse in the preceding and same interval predicted lower ICS implementation.
Patients may adapt their ICS use to their current needs without this impacting later RDAC.
吸入性糖皮质激素(ICS)依从性低与哮喘负担增加相关。这种关系可能是双向的,并且在依从性阶段(起始、实施和持续)可能有所不同。研究很少考察相互影响。
考虑双向性和时间顺序,调查ICS实施与2年期间哮喘相关结局之间的关系。
使用来自英国最佳患者护理研究数据库的初级保健记录(1987 - 2012年)。符合条件的患者年龄在6岁及以上,从ICS起始前1年(索引日期)开始有3年或更长时间的连续注册,医生诊断为哮喘,每年随访有2次或更多次ICS和/或短效β受体激动剂处方,且前一年无长效β受体激动剂、白三烯受体拮抗剂或维持性口服糖皮质激素。对每个处方间隔(连续两次处方之间的时间段)估计ICS实施情况(覆盖天数百分比)和风险领域哮喘控制(RDAC;无哮喘相关住院、急诊就诊或门诊就诊,且无口服糖皮质激素或抗生素处方且有呼吸检查证据)。多水平分析模拟了ICS实施与RDAC(及其组成部分)之间的双向关系,并控制了社会人口学和临床特征。
在10472例患者的处方数据中,前一个间隔的ICS实施情况不能预测RDAC,但与同期的RDAC呈弱正相关。男性、非当前吸烟者、无慢性阻塞性肺疾病诊断以及合并症少于4种显著增加了RDAC的几率。同一间隔内的哮喘相关抗生素和门诊就诊以及前一个和同一间隔内短效β受体激动剂的过度使用预示着较低的ICS实施情况。
患者可能会根据当前需求调整ICS的使用,而这不会影响随后的RDAC。